{"entity":{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","aka":["PentixaFor PET","CXCR4 PET in primary aldosteronism"],"tldr":"A common and curable cause of high blood pressure is almost never cured, because finding out which adrenal gland is at fault needs an invasive procedure few hospitals do well. A PET scan can answer the same question, and one is now heading into a registrational trial.","summary":"Primary aldosteronism accounts for 5 to 14% of all hypertension and 20 to 25% of treatment-resistant hypertension, and it can be cured by removing one adrenal gland if the excess comes from one side. Establishing which side requires adrenal vein sampling, an invasive procedure that the MATCH investigators describe as requiring a day off work, causing severe pain and hospitalisation in 1 to 3% of patients, available with a success rate above 50% in few hospitals. The consequence they report is stark: fewer than 1% of patients with primary aldosteronism are identified and fully investigated.\n\nThis is not a radiopharmaceutical looking for a use. It is the clearest standalone diagnostic case outside oncology, and it is already being built. 68Ga-PentixaFor from Pentixapharm holds EMA PRIME status granted in October 2024 and FDA Fast Track designation granted in July 2026, with an IND cleared and a phase 3 trial, PANDA, planned at approximately 270 patients in the United States. The academic evidence behind it is substantial: in a 100-patient prospective study, PET/CT agreed with adrenal vein sampling in 90% of patients against 54% for conventional CT, and a meta-analysis of seven studies covering 603 patients has been reported at pooled sensitivity 80% and specificity 91%.\n\nThe agent is also validated against pathology rather than just against another test: consistency between PET uptake and CXCR4 staining was 92.9%, and all 43 CYP11B2-positive functional nodules in one series were CXCR4-positive. What makes this record worth carrying is not that anything is missing, but that it is the field's best worked example of what an unmet-need-first opportunity looks like when it succeeds.","asOf":"2026-09-23","links":[{"label":"MATCH: molecular imaging against adrenal vein sampling, Nature Medicine 2023","url":"https://www.nature.com/articles/s41591-022-02114-5"},{"label":"68Ga-pentixafor against adrenal vein sampling in 100 patients, JAMA Network Open 2023","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9936343/"},{"label":"FDA Fast Track designation for 68Ga-PentixaFor in primary aldosteronism","url":"https://www.eqs-news.com/news/corporate/pentixapharm-receives-fda-fast-track-designation-for-phase-3-diagnostic-candidate-e281b6e281b8gaga-pentixafor-in-primary-aldosteronism/239d14bc-6e9e-4077-9909-43e52edf7a09_en"},{"label":"EMA PRIME status for 68Ga-PentixaFor","url":"https://www.pentixapharm.com/news/ema-grants-prime-status-to-pentixapharms-lead-candidate-pentixafor"},{"label":"68Ga-pentixafor dosimetry, J Nucl Med 2015","url":"https://jnm.snmjournals.org/content/56/3/410"},{"label":"Endocrine Society primary aldosteronism guideline 2025","url":"https://www.endocrine.org/clinical-practice-guidelines/primary-aldosteronism-2"}],"tags":["unmet need first","standalone diagnostic","non-oncology","hypertension"],"related":["ga-68"],"indications":["primary-aldosteronism"],"sections":[],"technologies":["pet-ct","pet"],"targets":["cxcr4"],"drugs":["ga-68-pentixafor"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"lens":"unmet-need-first","unmetNeed":"A curable cause of hypertension goes untreated because the test that decides who can be cured is invasive, painful, available in few centres and therefore almost never done: fewer than 1% of patients with primary aldosteronism are fully investigated.","useCase":"An endocrinologist or hypertension specialist with a confirmed diagnosis of primary aldosteronism would use the scan to decide between adrenalectomy and lifelong medical therapy, replacing adrenal vein sampling. The value is measured in operations correctly offered, not in lesions detected.","hypothesis":"CXCR4-targeted PET will lateralise primary aldosteronism accurately enough to replace adrenal vein sampling, and by removing the invasive step will raise the proportion of patients investigated and cured well above the current figure of fewer than 1%.","rationale":"CXCR4 is expressed on aldosterone-producing tissue and tracks the pathology marker: all CYP11B2-positive functional nodules in one series were CXCR4-positive, with 92.9% consistency between PET uptake and staining. Against the invasive reference standard, PET/CT concordance was 90% against CT's 54% in 100 patients, and surgical outcomes support it, with complete biochemical and clinical success of 91.67% and 100% in 36 patients operated on the basis of PET lateralisation. The molecular-imaging approach has already been shown non-inferior to adrenal vein sampling with a different tracer in the MATCH trial, so the regulatory logic is established.","test":"The registrational design is already defined: a multicentre trial benchmarking PET lateralisation against a performance standard derived from guideline-based diagnosis, with post-adrenalectomy biochemical and clinical cure as the outcome that matters. The open question this record tracks is whether phase 3 reproduces the 90% concordance seen in single-centre studies.","maturity":"being-tested-at-scale","verdict":"standalone-only","mostAdvanced":"68Ga-PentixaFor (Pentixapharm Holding AG): EMA PRIME status October 2024, FDA Fast Track July 2026, IND cleared, phase 3 PANDA planned at approximately 270 patients in the United States with US launch targeted for 2030.","dueDiligence":[{"domain":"target-biology","state":"strong","why":"All 43 CYP11B2-positive functional nodules in one series were CXCR4-positive, and consistency between PET uptake and CXCR4 staining was 92.9%, tying the imaging signal directly to the enzyme that makes aldosterone.","source":"Functional nodules study, PMID 36070092","url":"https://pubmed.ncbi.nlm.nih.gov/36070092/","weighted":true},{"domain":"clinical-evidence","state":"strong","why":"Multiple completed prospective studies including 100 patients against adrenal vein sampling, 120 patients with pathology correlation, and a randomised 320-patient trial recruiting in China; an approximately 270-patient US phase 3 is planned.","source":"Hu et al., JAMA Network Open 2023","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9936343/","weighted":true},{"domain":"diagnostic-performance","state":"strong","why":"PET/CT agreed with adrenal vein sampling in 90 of 100 patients against 54 of 100 for conventional CT; a reported meta-analysis of seven studies and 603 patients gives pooled sensitivity 80% and specificity 91% with an AUC of 0.91.","source":"Hu et al., JAMA Network Open 2023; meta-analysis via a 2026 review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9936343/","weighted":true},{"domain":"safety-dosimetry","state":"strong","why":"Effective dose from 150 MBq of 68Ga-pentixafor is 2.3 mSv, with the highest organ dose in the bladder wall at 12.2 mGy; a 2025 dosimetry paper reports 1.65 plus or minus 0.06 mSv for the same activity, both far below the 7 mSv of a standard FDG scan.","source":"Herrmann et al., J Nucl Med 2015","url":"https://jnm.snmjournals.org/content/56/3/410","weighted":true},{"domain":"regulatory-path","state":"strong","why":"EMA PRIME and FDA Fast Track are both granted for this exact indication, the IND has cleared, and written FDA minutes reportedly identified no major concerns with the phase 3 design.","source":"Pentixapharm and EQS releases","url":"https://www.eqs-news.com/news/corporate/pentixapharm-receives-fda-fast-track-designation-for-phase-3-diagnostic-candidate-e281b6e281b8gaga-pentixafor-in-primary-aldosteronism/239d14bc-6e9e-4077-9909-43e52edf7a09_en","weighted":true}],"flags":[{"category":"technical","flag":"green","why":"Gallium-68 small-molecule ligand, same-day imaging, effective dose around 2 mSv, and pathology-validated uptake."},{"category":"unmet-need","flag":"green","why":"A curable disease in 5 to 14% of all hypertension where fewer than 1% of patients are fully investigated because the deciding test is invasive."},{"category":"ip","flag":"red","why":"The ligand was patented at the University of Würzburg and exclusively licensed to Pentixapharm in 2019, so the lead chemical series is not available."},{"category":"commercial","flag":"green","why":"Purely standalone: the scan replaces a procedure and depends on no drug approval, which is the strongest commercial structure a diagnostic can have."},{"category":"isotope","flag":"green","why":"Gallium-68 from a generator; no supply constraint."},{"category":"competition","flag":"red","why":"One sponsor holds PRIME, Fast Track and a cleared IND in this indication, and the metomidate tracers are an established academic alternative; a new entrant would be third at best."}],"competition":[{"name":"Pentixapharm Holding AG","what":"68Ga-PentixaFor: EMA PRIME, FDA Fast Track, IND cleared, phase 3 PANDA planned at approximately 270 patients, US launch targeted 2030.","stage":"phase 3 planned","url":"https://www.pentixapharm.com/news/ema-grants-prime-status-to-pentixapharms-lead-candidate-pentixafor"},{"name":"National Cancer Institute and NIDDK","what":"Investigator-initiated phase 2 of 68Ga-PentixaFor in hyperaldosteronism and hypercortisolism, 80 patients estimated.","stage":"phase 2 recruiting","url":"https://clinicaltrials.gov/study/NCT06246357"},{"name":"First Affiliated Hospital of Chongqing Medical University","what":"Multicentre randomised trial of PET/CT-guided against adrenal-vein-sampling-guided treatment, 320 participants estimated.","stage":"recruiting","url":"https://classic.clinicaltrials.gov/ct2/show/NCT06238232"},{"name":"UK academic consortium (Barts, Cambridge, Guy's)","what":"[11C]metomidate and [18F]CETO, the non-CXCR4 precedent: molecular imaging reported non-inferior to adrenal vein sampling in MATCH, 146 patients.","stage":"published","url":"https://www.nature.com/articles/s41591-022-02114-5"}],"differentiation":"The aldosterone-to-renin ratio screens for the disease but does not say which side; CYP11B2 immunohistochemistry confirms the answer only after the gland has been removed; and no blood or ctDNA test lateralises the disease before surgery. The comparator here is an invasive procedure, not another scan, which is why the health-economic case is unusually direct.","metrics":[{"label":"Concordance of 68Ga-pentixafor PET/CT with adrenal vein sampling against CT","value":"90 of 100 patients against 54 of 100","source":"Hu et al., JAMA Network Open 2023","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9936343/"},{"label":"Primary aldosteronism as a share of all hypertension","value":"5 to 14%","source":"Wu et al., Nature Medicine 2023","url":"https://www.nature.com/articles/s41591-022-02114-5"},{"label":"Patients with primary aldosteronism identified and fully investigated","value":"fewer than 1%","source":"Wu et al., Nature Medicine 2023","url":"https://www.nature.com/articles/s41591-022-02114-5"},{"label":"Post-adrenalectomy complete biochemical and clinical success after PET-guided surgery in bilateral lesions","value":"91.67% and 100% of 36 patients","source":"EJNMMI Research 2025","url":"https://link.springer.com/article/10.1186/s13550-025-01309-4"},{"label":"Effective dose from 150 MBq of 68Ga-pentixafor","value":"2.3 mSv","source":"Herrmann et al., J Nucl Med 2015","url":"https://jnm.snmjournals.org/content/56/3/410"}],"risks":["Single-centre concordance of 90% may not survive a multicentre phase 3 with central reading.","The indication sits with endocrinologists and hypertension specialists who do not routinely order PET, so adoption is a referral-pathway problem as much as an accuracy one.","The chemical series is exclusively licensed, so this is a record to learn the method from rather than an opening to enter."],"watch":["Registration of PANDA on ClinicalTrials.gov and its first patient enrolled, expected in the second half of 2026 per the sponsor.","The Chongqing randomised trial, which is the only design that tests whether PET-guided treatment produces the same cures as sampling-guided treatment.","Whether guideline bodies begin to name molecular imaging as an alternative to adrenal vein sampling."]},"route":"/opportunities/opp-cxcr4-primary-aldosteronism/","neighbours":{"isotope":[{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"}],"indication":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"}],"target":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/"}],"drug":[{"id":"ga-68-pentixafor","kind":"drug","name":"Gallium-68 pentixafor","route":"/drugs/ga-68-pentixafor/"}]}}